Fc Engineering: Design, expression, and functional characterization of antibody variants with improved effector function

Methods in Molecular Biology

Volumn 907, Issue , 2012, Pages 519-536

  Derer, Stefanie ^a   Kellner, Christian ^a   Berger, Sven ^a   Valerius, Thomas ^a   Peipp, Matthias ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

ADCC; Antibody engineering; CDC

Indexed keywords

EID: 84867835452     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-974-7_30     Document Type: Article

References (32)

1. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of prede fi ned speci fi city. Nature 256:495-497
2. Press OW, Appelbaum F et al (1987) Monoclonal antibody 1 F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 694:584-591
3. Ehrlich P (1900) On immunity with special reference to cell life. Proc Royal Soc London 66:424-448
4. Neuberger MS, Williams GT et al (1985) A hapten-speci fi c chimaeric IgE antibody with human physiological effector function. Nature 314:268-270
5. Riechmann L, Clark M et al (1988) Reshaping human antibodies for therapy. Nature 332: 323-327
6. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357
7. Jefferis R, Lund J et al (1995) Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol Lett 44: 111-117
8. Lund J, Takahashi N et al (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and in fl uence the synthesis of its oligosaccharide chains. J Immunol 157:4963-4969
9. Jefferis R, Lund J et al (1998) IgG-Fc-mediated effector functions: molecular de fi nition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 163:59-76
10. Umana P, Jean-Mairet J et al (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176-180
11. Hodoniczky J, Zheng YZ et al (2005) Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21:1644-1652
12. Scallon BJ, Tam SH et al (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524-1534
13. Houde D, Peng Y et al (2010) Post-translational modi fi cations differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9:1716-1728
14. Peipp M, Lammerts van Bueren J et al (2008) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112:2390-2399
15. Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226-234
16. Kanda Y, Yamane-Ohnuki N et al (2006) Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng 94:680-688
17. Imai-Nishiya H, Mori K et al (2007) Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol 7:84
18. Shields RL, Lai J et al (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740
19. Shields RL, Namenuk AK et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591-6604
20. Lazar GA, Dang W et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103: 4005-4010
21. Presta LG, Shields RL et al (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30:487-490
22. Stavenhagen JB, Gorlatov S et al (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-af fi nity activating Fcgamma receptors. Cancer Res 67: 8882-8890
23. Idusogie EE, Wong PY et al (2001) Engineered antibodies with increased activity to recruit complement. J Immunol 166:2571-2575
24. Desjarlais JR, Lazar GA et al (2007) Optimizing engagement of the immune system by antitumor antibodies: an engineer's perspective. Drug Discov Today 12:898-910
25. Repp R, Kellner C et al (2011) Combined Fc-protein-and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods 373(1-2):67-78
26. Boel E, Verlaan S et al (2000) Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239:153-166
27. Harlow E, Lane D (1988) Antibodies-a laboratory manual. Cold Spring Harbor Laboratory Press, New York, NY
28. Clark MR (1997) IgG effector mechanisms. Chem Immunol 65:88-110
29. Peipp M, van de Winkel JG et al (2011) Molecular engineering to improve antibodies' anti-lymphoma activity. Best Pract Res Clin Haematol 24:217-229
30. Moore GL, Chen H et al (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2:181-189
31. Ripka J, Adamany A et al. (1986) Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDPfucose. Arch Biochem Biophys 249(2): 533-545
32. Patnaik SK and Stanley P (2006) Lectinresistant CHO glycosylation mutants. Methods Enzymol 416:159-182